Table 2.
Mortality and tumor incidence in mice injected with 2.5 mg Ni3S2/thigh muscle1
| Group No. | Treatment | Total No. of mice | Mice dead in 1 week4 | No. of mice at tumor risk (surviving > 30 wks.) | Mice with injection site tumors5 | Tumor-bearing mice euthanized at week6 | ||
|---|---|---|---|---|---|---|---|---|
| No. | % total | No. | % at risk | |||||
|
| ||||||||
| 6 | Gulo-/-, 1002 | 18 | 14 | 77.8 | 3 | 2 | 66.7 | 38, 42 |
|
| ||||||||
| 7 | Gulo-/-, 3302 | 18 | 9 | 50.0 | 9 | 5 | 55.6 | 45, 48, 48, 48, 54 |
|
| ||||||||
| 8 | Gulo-/-, 3302/sham3 | 17 | 2 | 11.8 | 15 | 0 | 0 | No tumors |
|
| ||||||||
| 9 | WT | 24 | 11 | 45.8 | 12 | 3 | 25.0 | 48, 54, 57 |
|
| ||||||||
| 10 | WT, 3302 | 24 | 9 | 37.5 | 15 | 3 | 20.0 | 42, 54, 57 |
1
Thigh musculature of both hind limbs; at week 0
2
Mice offered 100 or 330 mg ascorbic acid-containing drinking water, respectively, from weaning to life termination
3
Mice injected with the injection vehicle only
4
Renal failure
5
Tumor in one leg only. No tumors were found at other sites of the body
6
When tumor reached approx. 1 cm in diameter